Tenderwize
Retour à la recherche

Open-house rebate agreements for Rivaroxaban film-coated tablets excluding 2.5 mg

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jul 03, 2027 · 308 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Rivaroxaban Filmtabletten, ausgenommen in der Wirkstärke 2,5 mg, ATC B01AF01

62/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

62 / 100

Complexité

58 / 100

Facteurs de risque

The notice states the arrangement is an open-house model and not a procurement procedure in the usual sense; legal reme...

Contract documents submitted through the wrong portal area are expressly forbidden; submission must go via the DTVP com...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Non-exclusive supply/rebate agreement for Rivaroxaban film-coated tablets, excluding 2.5 mg strength.
  • Open-house model with identical, non-individually negotiable contract terms.
Afficher le résumé complet

This is an open-house pharmaceutical supply arrangement by AOK Bayern for Rivaroxaban film-coated tablets excluding the 2.5 mg strength (CPV 33600000). It is explicitly described as non-exclusive and non-negotiated, with contracts offered to all interested pharmaceutical companies that meet the stated suitability requirement. The notice includes electronic and paper submission options via DTVP or by post, with strict monthly cut-off rules for contract start dates. No contract value is stated.

Risques

The notice states the arrangement is an open-house model and not a procurement procedure in the usual sense; legal reme...

Contract documents submitted through the wrong portal area are expressly forbidden; submission must go via the DTVP com...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.
  • Signed contract and completed annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be submitted.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreements for Rivaroxaban film-coated tablets excluding 2.5 mg

Open-house framework-style supply arrangement for Rivaroxaban film-coated tablets, excluding the 2.5 mg strength, for AOK Bayern. The lot description states that contract documents must be submitted via the communication area in the DTVP portal, not via the offer area. The lot is explicitly open to all interested pharmaceutical companies meeting the suitability requirement; information in the notice indicates a maximum of 999 operators may join.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Aug 2025 - Aug 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Jul 03, 2027

Détails de la procédure

Date de publication
13 Jul 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
457937-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30